Cargando…
It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes
Why not directly eradicate SABA from asthma management? The time to leave behind SABA in asthma management is now. We wasted enough time identifying the key issue in asthma morbidity and mortality. Please, eradicate SABA. https://bit.ly/3DU4mmo
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969308/ https://www.ncbi.nlm.nih.gov/pubmed/36861059 http://dx.doi.org/10.1183/23120541.00555-2022 |
| _version_ | 1784897693193076736 |
|---|---|
| author | Nannini, Luis J. |
| author_facet | Nannini, Luis J. |
| author_sort | Nannini, Luis J. |
| collection | PubMed |
| description | Why not directly eradicate SABA from asthma management? The time to leave behind SABA in asthma management is now. We wasted enough time identifying the key issue in asthma morbidity and mortality. Please, eradicate SABA. https://bit.ly/3DU4mmo |
| format | Online Article Text |
| id | pubmed-9969308 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99693082023-02-28 It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes Nannini, Luis J. ERJ Open Res Correspondence Why not directly eradicate SABA from asthma management? The time to leave behind SABA in asthma management is now. We wasted enough time identifying the key issue in asthma morbidity and mortality. Please, eradicate SABA. https://bit.ly/3DU4mmo European Respiratory Society 2023-02-27 /pmc/articles/PMC9969308/ /pubmed/36861059 http://dx.doi.org/10.1183/23120541.00555-2022 Text en Copyright ©The authors 2023 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
| spellingShingle | Correspondence Nannini, Luis J. It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes |
| title | It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes |
| title_full | It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes |
| title_fullStr | It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes |
| title_full_unstemmed | It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes |
| title_short | It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes |
| title_sort | it is time to end our love affair with short-acting β(2)-agonists in asthma? yes |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969308/ https://www.ncbi.nlm.nih.gov/pubmed/36861059 http://dx.doi.org/10.1183/23120541.00555-2022 |
| work_keys_str_mv | AT nanniniluisj itistimetoendourloveaffairwithshortactingb2agonistsinasthmayes |